Spectral Diagnostics enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis

21-Dec-2009 - Spectral Diagnostics Inc. and BioMS Medical Corp. announced that BioMS Medical and a syndicate of investors have invested $14 million in Spectral Diagnostics to advance Toraymyxin(TM), a treatment for severe sepsis, towards regulatory approval and commercialization in the United ...

BioMS Medical announces receipt of milestone payment from Eli Lilly and Company

US$10 million received based on the positive review of interim analysis for international pivotal multiple sclerosis trial

24-Sep-2008 - BioMS Medical Corp. announced that it has received the US$10 million milestone payment from its partner, Eli Lilly and Company. The milestone payment is based on the previously announced positive review of the scheduled interim analysis of the Company's pivotal phase II/III Canadian and ...

BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis

Milestone triggers $10 million payment from Eli Lilly and Company

15-Aug-2008 - BioMS Medical Corp. announced that the independent Drug Safety Monitoring Board (DSMB) for the MAESTRO-01 trial has conducted the scheduled interim analysis of efficacy and safety and has recommended that the trial continue to completion. MAESTRO-01 is the pivotal phase II/III Canadian and ...

BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board

22-Jul-2008 - BioMS Medical Corp. announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 (dirucotide) in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol. This was ...

BioMS Medical named Biotech Company of the Year

Company to receive Gold Leaf Award from BIOTECanada at BIO 2008

13-Jun-2008 - BioMS Medical Corp. announced that it has been selected to receive the Gold Leaf Award from BIOTECanada for "Company of the Year". BioMS Medical will be presented with this distinguished award on June 17, 2008 at the 2008 BIO International Convention in San Diego, California. "This award ...

BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial

14-Nov-2007 - BioMS Medical Corp. announced that more than 133 patients have been enrolled in its MAESTRO-03 U.S. pivotal phase III clinical trial of MBP8298 for the treatment of secondary progressive multiple sclerosis (SPMS). An interim safety and efficacy analysis will be performed on data from the first ...

BioMS Medical initiates enrollment in pivotal U.S. phase III multiple sclerosis trial

08-Jun-2007 - BioMS Medical Corp announced that the first patients have been enrolled in MAESTRO-03, its U.S. pivotal phase III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of multiple sclerosis. The randomized, double-blind study is enrolling approximately 510 secondary ...

BioMS Medical cleared by FDA to initiate pivotal phase III multiple sclerosis trial

23-Jan-2007 - BioMS Medical Corp announced that it has received clearance from the United States Food and Drug Administration (FDA) of its Investigational New Drug Application (IND) for the initiation of a pivotal phase III clinical trial to investigate the use of MBP8298 as a treatment for patients with ...

BioMS Medical receives additional patent for multiple sclerosis drug MBP8298 in the United States

06-Nov-2006 - BioMS Medical Corp announced that the University of Alberta has received additional patents for the Company's synthetic peptide therapeutic, MBP8298, for the treatment of multiple sclerosis (MS). BioMS Medical licenses these patents on an exclusive worldwide basis from the University of ...

BioMS Medical's MBP8298 shows five-year delay of disease progression in patients with multiple sclerosis

09-Mar-2006 - BioMS Medical Corp announced that its proprietary drug candidate MBP8298 delayed disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes. Treatment and follow-up of patients from a phase II clinical study demonstrated that patients in this DR2 ...